CoreCap Advisors
TRVI icon

CoreCap Advisors’s Trevi Therapeutics TRVI Stock Holding History

CoreCap Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$258 Hold
18
– – ﹤0.01% 2915
2026
Q2 		$336 Buy
+18
New +$262 ﹤0.01% 2930

Other funds holding TRVI

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
TCOT
Trust Company of Toledo Holland, Ohio $1.25B AUM 28.18% 1-Year Est. Return
PFS Partners
PFS Partners Mine Hill, New Jersey $246M AUM 22.61% 1-Year Est. Return
Harbour Capital Advisors
Harbour Capital Advisors Tysons Corner, Virginia $548M AUM 37.76% 1-Year Est. Return
Chapin Davis
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Albion Financial Group
Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

CoreCap Advisors's TRVI Position: Q3 2026 in Review

CoreCap Advisors held its Trevi Therapeutics (TRVI) position steady in Q3 2026 at 18 shares worth $258. The position accounts for ﹤0.01% of the portfolio, ranked #2915.

CoreCap Advisors first reported a position in TRVI in Q2 2026 and has held it in 2 quarters since. The position peaked at $336 in Q2 2026. 18 funds tracked by Wall St. Rank hold TRVI as of Q3 2026.

  • CoreCap Advisors held 18 shares of Trevi Therapeutics worth $258 as of Q3 2026.
  • CoreCap Advisors left its Trevi Therapeutics share count unchanged in Q3 2026.
  • Trevi Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #2915 holding.
  • CoreCap Advisors first reported a position in Trevi Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • CoreCap Advisors's Trevi Therapeutics position peaked at $336 in Q2 2026.
  • 18 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.